<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03033264</url>
  </required_header>
  <id_info>
    <org_study_id>0592-14-RMB</org_study_id>
    <nct_id>NCT03033264</nct_id>
  </id_info>
  <brief_title>Labor Induction With Dinoprostone in Oppose to Cervical Ripening Balloon as a Factor of BMI.</brief_title>
  <official_title>A Comparison Between Labor Induction With Dinoprostone and a Cervical Ripening Balloon in Women With a BMI&gt;30 as Oppose With a BMI&lt;30.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women with a BMI&gt;30 and women with a BMI&lt;30 will be divided in a randomized controlled manor
      to 4 groups depending on the mode of labor induction and BMI value:

        1. Dinoprostone in women with a BMI&gt;30.

        2. Dinoprostone in women with a BMI&lt;30.

        3. Cervical ripening balloon in women with a BMI&gt;30.

        4. Cervical ripening balloon in women with a BMI&lt;30. The subjects will be followed until
           labor, and information regarding the success of induction, mode of delivery and time of
           delivery will be collected from patients` electronic files.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized controlled test in which women with a BMI&gt;30 and women with a
      BMI&lt;30 will sign an informed consent and then divided to 4 groups depending on the mode of
      labor induction and BMI value:

        1. Dinoprostone in women with a BMI&gt;30.

        2. Dinoprostone in women with a BMI&lt;30.

        3. Cervical ripening balloon in women with a BMI&gt;30.

        4. Cervical ripening balloon in women with a BMI&lt;30. All subjects participating in the
           study will be induced for obstetrical indications alone.

      The subjects will be followed until labor, and information regarding the success of
      induction, mode of delivery and time of delivery will be collected from patients` electronic
      files.

      The participants will finish participation in the study after delivery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mode of delivery</measure>
    <time_frame>Up to 5 days.</time_frame>
    <description>Vaginal delivery in oppose to cesarean section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to delivery</measure>
    <time_frame>Up to 5 days.</time_frame>
    <description>Time from insertion of induction device\drug until delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction success.</measure>
    <time_frame>Up to 5 days.</time_frame>
    <description>Cervical dilatation and effacement after cessation of induction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal complications and outcome.</measure>
    <time_frame>Up to 5 days.</time_frame>
    <description>Any neonatal complications as mentioned In the neonate`s electronic file.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Induction of Labor</condition>
  <arm_group>
    <arm_group_label>BMI&gt;30+Dinoprostone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with a BMI&gt;30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI&lt;30+Dinoprostone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with a BMI&lt;30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI&gt;30+Cervical ripening balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with a BMI&gt;30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI&lt;30+Cervical ripening balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with a BMI&lt;30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone</intervention_name>
    <description>10 mg of a Dinoprostone vaginal insert.</description>
    <arm_group_label>BMI&gt;30+Dinoprostone</arm_group_label>
    <arm_group_label>BMI&lt;30+Dinoprostone</arm_group_label>
    <other_name>Prostaglandin E2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Double lumen cervical ripening balloon.</intervention_name>
    <description>Double lumen cervical ripening balloon.</description>
    <arm_group_label>BMI&gt;30+Cervical ripening balloon</arm_group_label>
    <arm_group_label>BMI&lt;30+Cervical ripening balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any pregnant woman at term with an obstetric indication for labor induction.

        Exclusion Criteria:

          -  Previous cesarean section.

          -  Positive Oxytocin challenge test.

          -  Positive contraction stress test.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ROY LAUTERBACH, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ROY LAUTERBACH, MD</last_name>
    <phone>0529432416</phone>
    <email>R_LAUTERBACH@RAMBAM.HEALTH.CO.IL</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam health care campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Lauterbach, MD</last_name>
      <phone>0529432416</phone>
      <email>r_lauterbach@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2016</study_first_submitted>
  <study_first_submitted_qc>January 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2017</study_first_posted>
  <last_update_submitted>April 14, 2018</last_update_submitted>
  <last_update_submitted_qc>April 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>ROY LAUTERBACH MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

